FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2775883441> ?p ?o ?g. }

• W2775883441 endingPage "1289.e2" @default.
• W2775883441 startingPage "1282" @default.
• W2775883441 abstract "Background & AimsA system is needed to determine the risk of patients with Barrett’s esophagus for progression to high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC). We developed and validated a model to determine of progression to HGD or EAC in patients with BE, based on demographic data and endoscopic and histologic findings at the time of index endoscopy.MethodsWe performed a longitudinal study of patients with BE at 5 centers in United States and 1 center in Netherlands enrolled in the Barrett’s Esophagus Study database from 1985 through 2014. Patients were excluded from the analysis if they had less than 1 year of follow-up, were diagnosed with HGD or EAC within the past year, were missing baseline histologic data, or had no intestinal metaplasia. Seventy percent of the patients were used to derive the model and 30% were used for the validation study. The primary outcome was development of HGD or EAC during the follow-up period (median, 5.9 years). Survival analysis was performed using the Kaplan-Meier method. We assigned a specific number of points to each BE risk factor, and point totals (scores) were used to create categories of low, intermediate, and high risk. We used Cox regression to compute hazard ratios and 95% confidence intervals to determine associations between risk of progression and scores.ResultsOf 4584 patients in the database, 2697 were included in our analysis (84.1% men; 87.6% Caucasian; mean age, 55.4 ± 20.1 years; mean body mass index, 27.9 ± 5.5 kg/m2; mean length of BE, 3.7 ± 3.2 cm). During the follow-up period, 154 patients (5.7%) developed HGD or EAC, with an annual rate of progression of 0.95%. Male sex, smoking, length of BE, and baseline-confirmed low-grade dysplasia were significantly associated with progression. Scores assigned identified patients with BE that progressed to HGD or EAC with a c-statistic of 0.76 (95% confidence interval, 0.72–0.80; P < .001). The calibration slope was 0.9966 (P = .99), determined from the validation cohort.ConclusionsWe developed a scoring system (Progression in Barrett’s Esophagus score) based on male sex, smoking, length of BE, and baseline low-grade dysplasia that identified patients with BE at low, intermediate, and high risk for HGD or EAC. This scoring system might be used in management of patients. A system is needed to determine the risk of patients with Barrett’s esophagus for progression to high-grade dysplasia (HGD) and esophageal adenocarcinoma (EAC). We developed and validated a model to determine of progression to HGD or EAC in patients with BE, based on demographic data and endoscopic and histologic findings at the time of index endoscopy. We performed a longitudinal study of patients with BE at 5 centers in United States and 1 center in Netherlands enrolled in the Barrett’s Esophagus Study database from 1985 through 2014. Patients were excluded from the analysis if they had less than 1 year of follow-up, were diagnosed with HGD or EAC within the past year, were missing baseline histologic data, or had no intestinal metaplasia. Seventy percent of the patients were used to derive the model and 30% were used for the validation study. The primary outcome was development of HGD or EAC during the follow-up period (median, 5.9 years). Survival analysis was performed using the Kaplan-Meier method. We assigned a specific number of points to each BE risk factor, and point totals (scores) were used to create categories of low, intermediate, and high risk. We used Cox regression to compute hazard ratios and 95% confidence intervals to determine associations between risk of progression and scores. Of 4584 patients in the database, 2697 were included in our analysis (84.1% men; 87.6% Caucasian; mean age, 55.4 ± 20.1 years; mean body mass index, 27.9 ± 5.5 kg/m2; mean length of BE, 3.7 ± 3.2 cm). During the follow-up period, 154 patients (5.7%) developed HGD or EAC, with an annual rate of progression of 0.95%. Male sex, smoking, length of BE, and baseline-confirmed low-grade dysplasia were significantly associated with progression. Scores assigned identified patients with BE that progressed to HGD or EAC with a c-statistic of 0.76 (95% confidence interval, 0.72–0.80; P < .001). The calibration slope was 0.9966 (P = .99), determined from the validation cohort. We developed a scoring system (Progression in Barrett’s Esophagus score) based on male sex, smoking, length of BE, and baseline low-grade dysplasia that identified patients with BE at low, intermediate, and high risk for HGD or EAC. This scoring system might be used in management of patients." @default.
• W2775883441 created "2018-01-05" @default.
• W2775883441 creator A5007542664 @default.
• W2775883441 creator A5017964935 @default.
• W2775883441 creator A5024380717 @default.
• W2775883441 creator A5025826957 @default.
• W2775883441 creator A5027560115 @default.
• W2775883441 creator A5041381652 @default.
• W2775883441 creator A5042869763 @default.
• W2775883441 creator A5043436651 @default.
• W2775883441 creator A5047915584 @default.
• W2775883441 creator A5052614725 @default.
• W2775883441 creator A5056998508 @default.
• W2775883441 creator A5058210354 @default.
• W2775883441 creator A5061280628 @default.
• W2775883441 creator A5062736539 @default.
• W2775883441 creator A5066123691 @default.
• W2775883441 creator A5068822894 @default.
• W2775883441 creator A5074754821 @default.
• W2775883441 creator A5084754858 @default.
• W2775883441 creator A5088638396 @default.
• W2775883441 date "2018-04-01" @default.
• W2775883441 modified "2023-10-18" @default.
• W2775883441 title "Development and Validation of a Model to Determine Risk of Progression of Barrett’s Esophagus to Neoplasia" @default.
• W2775883441 cites W1522642799 @default.
• W2775883441 cites W1963825561 @default.
• W2775883441 cites W1985822229 @default.
• W2775883441 cites W1991552417 @default.
• W2775883441 cites W2003511196 @default.
• W2775883441 cites W2013407994 @default.
• W2775883441 cites W2026449750 @default.
• W2775883441 cites W2037195555 @default.
• W2775883441 cites W2040143851 @default.
• W2775883441 cites W2057328533 @default.
• W2775883441 cites W2059497743 @default.
• W2775883441 cites W2066962389 @default.
• W2775883441 cites W2091483584 @default.
• W2775883441 cites W2101235315 @default.
• W2775883441 cites W2101720796 @default.
• W2775883441 cites W2117981040 @default.
• W2775883441 cites W2122576282 @default.
• W2775883441 cites W2126327372 @default.
• W2775883441 cites W2132137210 @default.
• W2775883441 cites W2144409354 @default.
• W2775883441 cites W2146926950 @default.
• W2775883441 cites W2150063540 @default.
• W2775883441 cites W2154655874 @default.
• W2775883441 cites W2155625825 @default.
• W2775883441 cites W2161179649 @default.
• W2775883441 cites W2187093113 @default.
• W2775883441 cites W2231239302 @default.
• W2775883441 cites W2484192585 @default.
• W2775883441 cites W2604425045 @default.
• W2775883441 cites W4242240735 @default.
• W2775883441 cites W84710912 @default.
• W2775883441 doi "https://doi.org/10.1053/j.gastro.2017.12.009" @default.
• W2775883441 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29273452" @default.
• W2775883441 hasPublicationYear "2018" @default.
• W2775883441 type Work @default.
• W2775883441 sameAs 2775883441 @default.
• W2775883441 citedByCount "96" @default.
• W2775883441 countsByYear W27758834412018 @default.
• W2775883441 countsByYear W27758834412019 @default.
• W2775883441 countsByYear W27758834412020 @default.
• W2775883441 countsByYear W27758834412021 @default.
• W2775883441 countsByYear W27758834412022 @default.
• W2775883441 countsByYear W27758834412023 @default.
• W2775883441 crossrefType "journal-article" @default.
• W2775883441 hasAuthorship W2775883441A5007542664 @default.
• W2775883441 hasAuthorship W2775883441A5017964935 @default.
• W2775883441 hasAuthorship W2775883441A5024380717 @default.
• W2775883441 hasAuthorship W2775883441A5025826957 @default.
• W2775883441 hasAuthorship W2775883441A5027560115 @default.
• W2775883441 hasAuthorship W2775883441A5041381652 @default.
• W2775883441 hasAuthorship W2775883441A5042869763 @default.
• W2775883441 hasAuthorship W2775883441A5043436651 @default.
• W2775883441 hasAuthorship W2775883441A5047915584 @default.
• W2775883441 hasAuthorship W2775883441A5052614725 @default.
• W2775883441 hasAuthorship W2775883441A5056998508 @default.
• W2775883441 hasAuthorship W2775883441A5058210354 @default.
• W2775883441 hasAuthorship W2775883441A5061280628 @default.
• W2775883441 hasAuthorship W2775883441A5062736539 @default.
• W2775883441 hasAuthorship W2775883441A5066123691 @default.
• W2775883441 hasAuthorship W2775883441A5068822894 @default.
• W2775883441 hasAuthorship W2775883441A5074754821 @default.
• W2775883441 hasAuthorship W2775883441A5084754858 @default.
• W2775883441 hasAuthorship W2775883441A5088638396 @default.
• W2775883441 hasConcept C121608353 @default.
• W2775883441 hasConcept C126322002 @default.
• W2775883441 hasConcept C207103383 @default.
• W2775883441 hasConcept C2775894508 @default.
• W2775883441 hasConcept C2776497702 @default.
• W2775883441 hasConcept C2777819096 @default.
• W2775883441 hasConcept C2778589982 @default.
• W2775883441 hasConcept C2780221984 @default.
• W2775883441 hasConcept C2781182431 @default.
• W2775883441 hasConcept C2992824209 @default.
• W2775883441 hasConcept C44249647 @default.

• next